MedTrace Logo

Efficacy of Erenumab in Chronic Cluster Headache

NCT04970355 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2024-01-23

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the efficacy of erenumab in participants with chronic cluster headache.

Conditions

  • Cluster Headache
  • Trigeminal Autonomic Cephalalgias
  • Headache Disorders, Primary
  • Brain Disease

Interventions

BIOLOGICAL

Erenumab

Pre-filled syringe; s.c. injection

DRUG

Placebo

Pre-filled syring; s.c. injection

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Uwe Reuter, MD · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2023-09-27
Completion
2023-09-27
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04970355 on ClinicalTrials.gov